

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

In connection with the UBS report issued today on the potential impact of inhibitors of the neonatal receptor of the C fragment (FcRn inhibitors) to Grifols immunoglobulin business, the company strongly disagrees with the conclusions of the report based on the following aspects:

- The report is based solely on preliminary clinical studies (phase I and phase II) with a very limited number of patients and therefore results are not conclusive with regard to safety and efficacy of the products to treat some autoimmune diseases
- The product, to be approved after phase III trials, must prove equal or superior efficacy to immunoglobulin
- Even if safety and efficacy were demonstrated, FcRn would only impact a limited number of diseases and patients. For that reason the company believes the potential impact on its business would be minimal
- Demand for immunoglobulin well exceeds supply. The company continues innovating and developing new opportunities for the use of immunoglobulins and guaranteeing access for patients to the product by investing in plasma supply and new production facilities.

In Barcelona, on 3 October 2018

Nuria Martín Barnés
Secretary to the Board of Directors